Holen Sie sich die Stockscreener-App
1.865
0.80%
-0.015
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
Cabaletta Bio (Nasdaq: CABA) offers webcasts across Nov–Dec conferences; 30-day replays - Stock Titan
Gossamer Bio Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October - Defense World
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site - GlobeNewswire Inc.
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
Tourmaline Bio Announces Board and Executive Resignations Following Merger - TradingView
Why Nuvation Bio Inc. stock is a must watch in 2025Trade Entry Report & Long-Term Safe Investment Ideas - fcp.pa.gov.br
Cabaletta Bio, Inc. Presents Clinical Data and Updates at ACR Convergence 2025 - TradingView
INmune Bio (NASDAQ: INMB) schedules results call for 4:30 PM ET on Oct 30 - Stock Titan
Q32 Bio Inc Completes Enrollment in SIGNAL-AA Phase 2a Trial - TradingView
[8-K] bioAffinity Technologies, Inc. Reports Material Event | BIAF SEC FilingForm 8-K - Stock Titan
PALI annual meeting: directors elected, auditor ratified, split approved - Stock Titan
Stop Loss: Why Nuvation Bio Inc. stock is popular among millennials2025 Sector Review & Breakout Confirmation Alerts - Trung tâm Dự báo KTTV quốc gia
Samsung to invest $110 mn in Grail to bring early-cancer test to Asia - KED Global
Climb Bio Publishes Long-Term Data on Budoprutug - TradingView
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 - Stock Titan
CLYM reports budoprutug Phase 1b follow-up: 3-year control in 4 pts - Stock Titan
Palisade Bio Provides Corporate and Compliance Update - TradingView
PALI back in Nasdaq bid-price compliance; 133.0M shares out - Stock Titan
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
ANVS prices $6.0M offering; adds pre-funded and agent warrants - Stock Titan
[8-K] – Inmune Bio, Inc. (INMB) (CIK 0001711754) - Stock Titan
Inmune Bio Inc Announces Participation in Dermatologic Panel - TradingView
Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC - Stock Titan
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership - Reuters
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewswire
Is Mustang Bio Inc. stock ready for a breakoutJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
OrbiMed Funds Buy into Adicet Bio Offering; Ownership Diluted to 9.6% - Stock Titan
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
TELA insider award: 11,925 RSUs; option for 17,550 shares at $1.48 - Stock Titan
Korro Bio, Inc. (KRRO) Stock Price, News, Quote & History - Yahoo
TELA (TELA) Initial Form 3 — Director Records Zero Holdings - Stock Titan
Palisade Bio, Inc. Cancels Special Meeting of Stockholders - TradingView
[8-K] PALISADE BIO, INC. Reports Material Event | PALI SEC FilingForm 8-K - Stock Titan
[SCHEDULE 13G] PALISADE BIO, INC. SEC Filing - Stock Titan
Perceptive Discloses 9.99% Stake in Palisade Bio (12.24M Shares) - Stock Titan
PALI grants 7,665,800 RSUs to Chief Medical Officer; vesting over 2 years - Stock Titan
PALI Form 4: 9.18M RSUs granted to director/officer - Stock Titan
Bio, semiconductor, content firms to reboot Korea’s IPO market - KED Global
Commodore Capital and principals disclose 9.9% holding in PALI - Stock Titan
Deep Track discloses 6.43M pre-funded warrants, holds 9.99% of PALI - Stock Titan
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
[8-K] Adicet Bio, Inc. Reports Material Event | ACET SEC FilingForm 8-K - Stock Titan
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Adicet's ADI-001 yields immune-reset signals; Phase 2 targeted Q2 2026 - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
Biopsy Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Increasing Surgical Procedures | DelveInsight - The Globe and Mail
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Wheeler Bio Appoints Jay Benson as Chief Operating Officer - PR Newswire
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - Yahoo Finance
$120 Million Stock Offering: Biotech Palisade Bio Prices Massive 171.4M Share Public Offering at $0.70 - Stock Titan
Biotech Adicet Bio Issues New Employee Stock Options at $0.81 Under Special Inducement Plan - Stock Titan
Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Stock Offering at $2.50 - Stock Titan
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
180-Patient Phase 3 Trial: Nuvation Bio Tests IBTROZI for Early-Stage Lung Cancer Prevention - Stock Titan
Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential - Investing.com India
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN - GlobeNewswire
1.85%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):